Company
FIMECS, Inc.
PhaiMeX is a drug discovery venture company advancing research and development of novel drugs whose mechanism of action is protein degradation.
Also known as FIMECS
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Founded
- 2018
- Customers
- 国内外の企業、研究機関
- Legal name
- ファイメクス株式会社
Record updated 18 September 2026
About
Phimex is a drug discovery venture company that conducts research and development of novel drugs whose mechanism of action is protein degradation. Based on its proprietary E3 ligase-binding molecules and its drug discovery platform technology "RaPPIDS™", it is advancing multiple first-in-class drug development programs targeting proteins that have been considered "undruggable". By using RaPPIDS™ not only for in-house projects but also in joint research with companies and research institutions in Japan and abroad, the company will address a wide range of drug targets and unmet medical needs, and provide life-saving medicine for patients and their families around the world.